Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dyskinesia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    126 result(s) found for: Dyskinesia. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2011-004211-23 Sponsor Protocol Number: PI11-PR-KRYSTKOWIAK Start Date*: 2011-11-08
    Sponsor Name:CHU Amiens
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10043118 Tardive dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001685-35 Sponsor Protocol Number: ADT-2022-003 Start Date*: 2022-12-27
    Sponsor Name:Adeptio Pharmaceuticals Limited
    Full Title: Randomized, double-blind, placebo controlled clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia.
    Medical condition: Tardive dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10043118 Tardive dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000271-39 Sponsor Protocol Number: 2022-01 Start Date*: 2022-09-02
    Sponsor Name:Adeptio Pharmaceuticals Ltd
    Full Title: Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)
    Medical condition: Tardive dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10043118 Tardive dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-006004-16 Sponsor Protocol Number: 03PDE2020 Start Date*: 2021-07-16
    Sponsor Name:Celon Pharma S.A.
    Full Title: Phase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A inhibitor) in Patients with Parkinson's Diseas...
    Medical condition: Levodopa-induced dyskinesia in Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001302-27 Sponsor Protocol Number: N01142 Start Date*: 2005-06-10
    Sponsor Name:UCB S.A. Pharma Sector
    Full Title: An 8-week exploratory, double-blind, placebo controlled, randomized trial : Evaluation of the efficacy and safety of levetiracetam up to 3000 mg/day (250-500 mg oral tablets in b.i.d. administratio...
    Medical condition: Tardive dyskinesia usually occurs after prolonged exposure to antipsychotics and is characterized by abnormal choreiform, athetoic, choreathetoic or rhythmic involuntary movements. The localizatio...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10013928 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003458-18 Sponsor Protocol Number: IRL790C003 Start Date*: 2017-12-19
    Sponsor Name:Integrative Research Laboratories AB (IRLAB)
    Full Title: A randomised, double-blind, placebo-controlled, phase IIA study evaluating the efficacy and tolerability of IRL790 in Parkinson's disease dyskinesia
    Medical condition: Parkinson's disease dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003739-20 Sponsor Protocol Number: ADS-AMT-PD302 Start Date*: 2015-04-23
    Sponsor Name:Adamas Pharmaceuticals, Inc.
    Full Title: Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa-Induced Dyskinesia
    Medical condition: Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10013916 Dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004664-58 Sponsor Protocol Number: BESTCILIA-WP5 Start Date*: 2014-08-26
    Sponsor Name:Paediatric Pulmonary Service, Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark
    Full Title: RANDOMIZED CONTROLLED TRIAL (RCT) TO DETERMINE THE EFFICACY AND SAFETY OF AZITHROMYCIN (AZN) MAINTENANCE THERAPY FOR 6 MONTHS IN SUBJECTS WITH PCD - A DOUBLE-BLIND, PARALLEL GROUP STUDY
    Medical condition: Primary ciliary dyskinesia (PCD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10069713 Primary ciliary dyskinesia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003738-24 Sponsor Protocol Number: ADS-AMT-PD304 Start Date*: 2015-04-23
    Sponsor Name:Adamas Pharmaceuticals, Inc.
    Full Title: ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients with Levodopa-Induced Dyskinesia
    Medical condition: Treatment of levodopa-induced dyskinesia in subjects with Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10013916 Dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022517-25 Sponsor Protocol Number: ADX48621-201 Start Date*: 2011-05-30
    Sponsor Name:Addex Pharma SA
    Full Title: Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesi...
    Medical condition: Levodopa induced dyskinesia in Parkinson's disease patients
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10013916 Dyskinesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003415-19 Sponsor Protocol Number: JM-010CS03 Start Date*: 2018-10-31
    Sponsor Name:Contera Pharma
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Co...
    Medical condition: Parkinson’s Disease Patients With Moderate to Severe Dyskinesia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-001593-10 Sponsor Protocol Number: EMR 62225-018 Start Date*: 2004-12-02
    Sponsor Name:MERCK S.P.A.
    Full Title: A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from t...
    Medical condition: Treatment-Associated Dyskinesia in Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-006053-22 Sponsor Protocol Number: NLX-112-DYS-101 Start Date*: 2021-09-22
    Sponsor Name:Neurolixis SAS
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 versus Placebo in Levodopa-induced Dyskinesia in Parkinson’s Disease
    Medical condition: Parkinson´s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001594-25 Sponsor Protocol Number: EMR62225-019 Start Date*: 2004-12-30
    Sponsor Name:Merck KGaA
    Full Title: A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from t...
    Medical condition: Treatment-Associated Dyskinesia in Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001403-23 Sponsor Protocol Number: M15-535 Start Date*: 2017-02-22
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with ...
    Medical condition: Dyskinesia in advanced Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) GR (Completed) ES (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000444-84 Sponsor Protocol Number: EMR62225-030 Start Date*: 2005-06-22
    Sponsor Name:Merck KGaA
    Full Title: An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from...
    Medical condition: Treatment-Associated Dyskinesia in Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) FI (Prematurely Ended) GB (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002010-41 Sponsor Protocol Number: IRL790C005 Start Date*: 2020-12-22
    Sponsor Name:Integrative Research Laboratories Sweden AB (IRLAB)
    Full Title: A randomized, double-blind, placebo-controlled phase IIB study evaluating the efficacy of mesdopetam on DAILY on-time without troublesome dyskinesia in patients with Parkinson’s disease
    Medical condition: Parkinson's disease dyskinesia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002073-30 Sponsor Protocol Number: CAFQ056A2222 Start Date*: 2011-11-16
    Sponsor Name:Novartis Farmaceutica, S.A.
    Full Title: 12-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Par...
    Medical condition: L-dopa induced dyskinesias in patients with Parkinson?s disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10013929 Dyskinesias and movement disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002467-27 Sponsor Protocol Number: 2007 Neuro 12 Start Date*: 2008-01-24
    Sponsor Name:Salford Royal NHS Foundation Trust
    Full Title: Antidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias
    Medical condition: Patients with idiopathic Parkinson's disease and levodopa-induced dyskinesias
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10013916 Dyskinesia PT
    13.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    13.1 10029205 - Nervous system disorders 10034005 Parkinson's disease and parkinsonism HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001890-15 Sponsor Protocol Number: SD-809-C-18 Start Date*: 2014-11-12
    Sponsor Name:Auspex Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA
    Medical condition: Tardive Dyskinesia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 07:49:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA